摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(6-{4-[3-(4-piperonylpiperazine-1-carbonyl)piperidin-1-yl]phenoxy}pyridine-3-yl)-3,4-dichlorobenzamide | 875674-24-1

中文名称
——
中文别名
——
英文名称
N-(6-{4-[3-(4-piperonylpiperazine-1-carbonyl)piperidin-1-yl]phenoxy}pyridine-3-yl)-3,4-dichlorobenzamide
英文别名
N-(6-{4-[3-(4-piperonylpiperazine-1-carbonyl)piperidin-1-yl]phenoxy}pyridin-3-yl)-3,4-dichlorobenzamide;N-[6-[4-[3-[4-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbonyl]piperidin-1-yl]phenoxy]pyridin-3-yl]-3,4-dichlorobenzamide
N-(6-{4-[3-(4-piperonylpiperazine-1-carbonyl)piperidin-1-yl]phenoxy}pyridine-3-yl)-3,4-dichlorobenzamide化学式
CAS
875674-24-1
化学式
C36H35Cl2N5O5
mdl
——
分子量
688.61
InChiKey
LWMGFJJYBYFSPD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6
  • 重原子数:
    48
  • 可旋转键数:
    8
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    96.5
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
    申请人:Matsuyama Hironori
    公开号:US20100004438A1
    公开(公告)日:2010-01-07
    An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.
    本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明,提供了一种包含以下一般式(1)所表示的化合物或其盐作为活性成分的药物:[式1]其中X1代表氮原子或基团—CH═,R1代表一个基团-Z-R6,其中Z代表基团—CO—,基团—CH(OH)—或类似的基团,R6代表一个含有1至4个氮原子、氧原子或原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团,R2代表氢原子或卤原子,Y代表基团—O—,基团—CO—,基团—CH(OH)—或低碳烷基基团,A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团,p代表1或2,R4代表咪唑基低碳基团或类似基团。
  • Aromatic Compounds
    申请人:Fukushima Tae
    公开号:US20070270422A1
    公开(公告)日:2007-11-22
    The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.
    本发明提供了一种新型化合物,具有抑制胶原生成的优异效果,并且具有较少的副作用,在安全性方面表现出色。本发明的化合物由以下通式(1)表示:[其中X1代表氮原子或基团—CH═;R1代表基团-Z-R6,其中Z代表基团—CO—、基团—CH(OH)—或类似基团,而R6代表具有1到4个氮原子、氧原子或原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团;R2代表氢原子、卤素原子或低碳链基团;Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团;A代表基团或类似基团,其中R3代表氢原子、低碳醚基团或类似基团,p代表1或2,而R4代表咪唑基低碳基团或类似基团。
  • AROMATIC COMPOUND
    申请人:FUKUSHIMA Tae
    公开号:US20120238750A1
    公开(公告)日:2012-09-20
    The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group —Z—R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.
    本发明的化合物由以下通式(1)表示:[其中X1表示氮原子或基团—CH═; R1表示基团—Z—R6,其中Z表示基团—CO—、基团—CH(OH)—或类似物,而R6表示具有1至4个氮原子、氧原子或原子的5至15环的单环、双环或三环、饱和或不饱和的杂环基团; R2表示氢原子、卤素原子或较低的烷基链; Y表示基团—O—、基团—CO—、基团—CH(OH)—、较低的烷基链或类似物; A表示基团或类似物,其中R3表示氢原子、较低的烷氧基或类似物,p表示1或2,而R4表示咪唑基较低的烷基链或类似物。
  • STAT3/5 activation inhibitor
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP2612858A1
    公开(公告)日:2013-07-10
    An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: wherein X1 represents a nitrogen atom or a group -CH=, R1 represents a group -Z-R6, in which Z represents a group -CO-, a group -CH(OH)- or the like, R6 represents a 5-to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group -O-, a group -CO-, a group -CH(OH)- or a lower alkylene group, and A represents a group wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.
    本发明的目的是提供一种 STAT3/5 活化抑制剂。本发明提供了一种 STAT3/5 活化抑制剂,其活性成分含有通式所代表的芳香族化合物或其盐: 其中 X1 代表氮原子或基团-CH=,R1 代表基团-Z-R6,其中 Z 代表基团-CO-、基团-CH(OH)-或类似基团,R6 代表 5 至 15 元单环、R2 代表氢原子或卤素原子,Y 代表基团 -O-、基团 -CO-、基团 -CH(OH)- 或低级亚烷基,A 代表基团 其中 R3 代表氢原子、低级烷氧基或类似基团,p 代表 1 或 2,R4 代表咪唑低级烷基或类似基团。
  • AROMATIC COMPOUNDS
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP1773797A2
    公开(公告)日:2007-04-18
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺